JoVE Logo

S'identifier

When drugs are administered extravascularly, a comprehensive evaluation through noncompartmental analysis becomes imperative. This analytical approach considers various parameters that play a crucial role in understanding the pharmacokinetics of these drugs.

One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area under the concentration-time curve. Doing so provides valuable insights into the drug's mean absorption time (MAT) to reach the systemic circulation and its mean residence time (MRT) within the systemic circulation.

It is worth noting that regardless of the administration route, the mean residence time remains constant. However, the MRT significantly influences the drug's mean absorption and transit times. This observation underscores the importance of considering the residence time when analyzing the pharmacokinetic behavior of extravascularly administered drugs.

In the case of orally administered tablets or capsules, an additional parameter called mean dissolution time (MDT) comes into play. MDT explicitly evaluates the time required for the drug to dissolve in vivo. Its estimation is straightforward for immediate-release-type products, as they exhibit predictable dissolution patterns. In extended-release (ER) formulations, the release of the drug is controlled by various mechanisms, such as matrix systems, coatings, or osmotic pumps, which extend the dissolution process. The extended-release directly increases the MDT compared to immediate-release (IR) formulations.

To calculate the mean dissolution time, we must determine the difference between the mean transit time for a solution and the mean transit time for an immediate-release solid drug product. This distinction provides a valuable indication of the drug's dissolution characteristics and aids in understanding its behavior within the body.

By applying noncompartmental analysis and considering these parameters, researchers and healthcare professionals can understand how extravascularly administered drugs interact with the body, including their transit, absorption, residence, and dissolution processes. This knowledge enables them to make informed decisions regarding dosing regimens, therapeutic efficacy, and potential drug interactions.

Tags

Noncompartmental AnalysisMean Transit Time MTTMean Absorption Time MATMean Residence Time MRTMean Dissolution Time MDTPharmacokineticsExtravascular AdministrationOral Drug FormulationsImmediate release IRExtended release ERDrug DissolutionTherapeutic EfficacyDosing Regimens

Du chapitre 7:

article

Now Playing

7.28 : Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time

Pharmacokinetic Models

37 Vues

article

7.1 : Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Pharmacokinetic Models

55 Vues

article

7.2 : Model Approaches for Pharmacokinetic Data: Compartment Models

Pharmacokinetic Models

53 Vues

article

7.3 : One-Compartment Open Model for IV Bolus Administration: General Considerations

Pharmacokinetic Models

114 Vues

article

7.4 : One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

Pharmacokinetic Models

115 Vues

article

7.5 : One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance

Pharmacokinetic Models

45 Vues

article

7.6 : One-Compartment Model: IV Infusion

Pharmacokinetic Models

117 Vues

article

7.7 : One-Compartment Open Model for Extravascular Administration: Zero-Order Absorption Model

Pharmacokinetic Models

41 Vues

article

7.8 : One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model

Pharmacokinetic Models

163 Vues

article

7.9 : One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

Pharmacokinetic Models

225 Vues

article

7.10 : One-Compartment Open Model: Urinary Excretion Data and Determination of k

Pharmacokinetic Models

79 Vues

article

7.11 : Multicompartment Models: Overview

Pharmacokinetic Models

61 Vues

article

7.12 : Two-Compartment Open Model: Overview

Pharmacokinetic Models

77 Vues

article

7.13 : Two-Compartment Open Model: IV Bolus Administration

Pharmacokinetic Models

234 Vues

article

7.14 : Two-Compartment Open Model: IV Infusion

Pharmacokinetic Models

157 Vues

See More

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.